Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: We used data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study (n = 14,671), a cardiovascular (CV) safety trial adding sitagliptin versus placebo to usual care in patients with type 2 diabetes and ASCVD (median follow-up 3 years). An independent committee blinded to treatment assignment adjudicated each cause of death. Cox proportional hazards models were used to identify risk factors associated with each outcome. RESULTS: A total of 1,084 deaths were adjudicated as the following: 530 CV (1.2/100 patient-years [PY], 49% of deaths), 338 non-CV (0.77/100 PY, 31% of deaths), and 216 unknown (0.49/100 PY, 20% of deaths). The most common CV death was sudden death (n = 145, 27% of CV death) followed by acute myocardial infarction (MI)/stroke (n = 113 [MI n = 48, stroke n = 65], 21% of CV death) and heart failure (HF) (n = 63, 12% of CV death). The most common non-CV death was malignancy (n = 154, 46% of non-CV death). The risk of specific CV death subcategories was lower among patients with no baseline history of HF, including sudden death (hazard ratio [HR] 0.4; P = 0.0036), MI/stroke death (HR 0.47; P = 0.049), and HF death (HR 0.29; P = 0.0057). CONCLUSIONS: In this analysis of a contemporary cohort of patients with diabetes and ASCVD, sudden death was the most common subcategory of CV death. HF prevention may represent an avenue to reduce the risk of specific CV death subcategories.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial, which recruited ~1200 persons who were either hospitalized with HF or were recently discharged following hospitalization for HF, and all of whom had T2D, a mixed SGLT1/2 inhibitor sotagliflozin also significantly reduced the primary endpoint of total HF hospit”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [653]
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“For CV death, a further sensitivity analysis that used the Fine-Graymethod (11) accounted for the competing risk of non-CV and unknown causes of death, with results reported on the basis of subdistributional hazard functions.”
MethodEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 1×
“In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study (17), sudden death was the most commonly adjudicated cause of CV death (68 of 227 [29.”
BackgroundSelf-citationTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationStandards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,465
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A.-M., Kosiborod, M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Clements, M., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 996
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L. (2015) · Circulation · doi:10.1161/circulationaha.114.014796 · Cited by 501
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401 · cited 1×
“nized andmay be due to an increased risk of thrombotic events, electrolyte-induced arrhythmias, increased myocardial fibrosis, and autonomic dysfunction (26,27).”
BackgroundDiabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults
Campbell, P. T., Newton, C. C., Patel, A. V., Jacobs, E. J., & Gapstur, S. M. (2012) · Diabetes Care · doi:10.2337/dc12-0002 · Cited by 339
Uretsky, B. F., Thygesen, K., Armstrong, P. W., Cleland, J. G., Horowitz, J. D., Massie, B. M., Packer, M., Poole-Wilson, P. A., & Ryden, L. (2000) · Circulation · doi:10.1161/01.cir.102.6.611 · Cited by 334 · cited 1×
“The burden of thrombotic events contributing to sudden death among patients with diabetes also likely is underestimated (15).”
BackgroundSelf-citationMarijon, E., Le Heuzey, J.-Y., Connolly, S., Yang, S., Pogue, J., Brueckmann, M., Eikelboom, J., Themeles, E., Ezekowitz, M., Wallentin, L., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000491 · Cited by 314 · cited 1×
“Similar results have been seen in other disease states at higher risk for CV events, such as atrial fibrillation (22).”
ResultHeart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304 · cited 2×
“sudden death (5) and heart failure (HF) (6), and non-CV deaths, such as malignancy (4).”
BackgroundSelf-citationDiabetes, glucose level, and risk of sudden cardiac death
Jouven, X., Lemaître, R. N., Rea, T. D., Sotoodehnia, N., Empana, J.-P., & Siscovick, D. S. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi376 · Cited by 264 · cited 2×
“, cardiac autonomic dysfunction) and macrovascular disease (14).”
BackgroundImplantable Cardioverter–Defibrillators after Myocardial Infarction
Myerburg, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803409 · Cited by 146
Green, J. B., Bethel, M. A., Paul, S. K., Ring, A., Kaufman, K. D., Shapiro, D. R., Califf, R. M., & Holman, R. R. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.09.003 · Cited by 141 · cited 2×
“The main methods and results have been reported (9,10).”
BackgroundMethodSelf-citationCKD and Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapeutic Approaches
Whitman, I. R., Feldman, H. I., & Deo, R. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010037 · Cited by 134 · cited 1×
“nized andmay be due to an increased risk of thrombotic events, electrolyte-induced arrhythmias, increased myocardial fibrosis, and autonomic dysfunction (26,27).”
BackgroundImplantable cardioverter defibrillators after myocardial infarction.
Bonny, A., Ditah, I. C., & Tonga, N. (2009) · PubMed · Cited by 123
Sudden cardiac death after myocardial infarction in patients with type 2 diabetes
Junttila, J. M., Barthel, P., Myerburg, R. J., Mäkikallio, T. H., Bauer, A., Ulm, K., Kiviniemi, A. M., Tulppo, M. P., Perkiömäki, J. S., Schmidt, G. P., et al. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.07.031 · Cited by 99 · cited 1×
“Diabetes independently increases the risk for sudden death (13,14).”
BackgroundYang, X. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.5.451 · Cited by 98
Laukkanen, J. A., Mäkikallio, T. H., Ronkainen, K., Karppi, J., & Kurl, S. (2013) · Diabetes Care · doi:10.2337/dc12-0110 · Cited by 67 · cited 1×
“sudden death (5) and heart failure (HF) (6), and non-CV deaths, such as malignancy (4).”
BackgroundHeart failure event definitions in drug trials in patients with type 2 diabetes
Sharma, A., Bhatt, D. L., Calvo, G., Brown, N. J., Zannad, F. M., & Mentz, R. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00049-8 · Cited by 31 · cited 1×
“Although identifying a history of HF and subsequent HF events in clinical trials often is difficult (23), patients with diabetes are at a higher risk of developing HF (6,24,25).”
BackgroundSelf-citationSharma, A., Brito, F. D. S., Sun, J., Thomas, L. E., Haffner, S. M., Holman, R. R., & Lópes, R. D. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.12.011 · Cited by 23 · cited 1×
“Among patientswith prediabetes and risk factors for CV disease, non-CV deaths, specifically malignancy, contribute to the large burden of all-cause mortality (4,7).”
BackgroundSelf-citationDiabetes, Impaired Fasting Glucose, and Heart Failure: Its not All About the Sugar
Sharma, A., & Ezekowitz, J. A. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.179 · Cited by 22 · cited 1×
“Although identifying a history of HF and subsequent HF events in clinical trials often is difficult (23), patients with diabetes are at a higher risk of developing HF (6,24,25).”
BackgroundSelf-citation
Research works printed but not linked: 1
- International Diabetes Federation, 2015, IDF Diabetes Atlas
Cited by
Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T. B., Schnell, O., Standl, E., & Beulens, J. W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319878371 · Cited by 1,009
“After sudden cardiac death, which represents the largest subcategory of cardiovascular death in subjects with T2DM and established ASCVD (27% of cardiovascular deaths), acute myocardial infarction (MI), along with stroke, represents the second most lethal complication (21%).(11) Several follow-up studies came to the s…”
BackgroundSelf-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
The global epidemics of diabetes in the 21st century: Current situation and perspectives
Standl, E., Khunti, K., Hansen, T. B., & Schnell, O. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319881021 · Cited by 497
“as studied in the TECOS trial, more than 50% of all deaths are due to cardiovascular causes, with sudden death being the most common cause, followed by combined death from myocardial infarction or stroke, and death from heart failure.(36) Particularly high death rates are unfortunately still reported for young-onset t…”
BackgroundSelf-citationCardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 110
Self-citation
Metadata
- Authors
- Sharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., Kaufman, K. D., Standl, E., Chan, J. C. N., Distiller, L. A., Scott, R., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of Alberta (CA)
- Duke University (US)
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
- University of North Carolina at Chapel Hill (US)
- George Washington University (US)
- University of Leuven, Leuven, Belgium
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Helmholtz Munich (DE)
- Chinese University of Hong Kong (HK)
- Centre for Diabetes and Endocrinology, Johannesburg, South Africa
- Christchurch Hospital (NZ)
- University of Oxford (GB)
- Corresponding author
- Sharma, Abhinav
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-10-06
- Volume
- 40
- Issue
- 12
- Pages
- 1763-1770
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2763921543
- Cited by
- 80
- References
- 27
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 4 · 2022: 6 · 2021: 16 · 2020: 19 · 2019: 14 · 2018: 4 · 2017: 2
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Merck & Co.
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, atherosclerotic cardiovascular disease, causes of death, cardiovascular mortality, sudden death, acute myocardial infarction, stroke, heart failure, cancer mortality, sitagliptin, TECOS trial, heart failure prevention
- MeSH terms
- Sitagliptin Phosphate, Aged, Cause of Death, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.